

FOR IMMEDIATE RELEASE

Boson Announces Exclusive U.S. Distribution Agreement with LumiQuick Diagnostics Inc.

Release Date

August 4, 2022

Xiamen Boson Biotech Co., Ltd. (“Boson”) is pleased to announce a newly formed strategic partnership with LumiQuick Diagnostics Inc. (“LumiQuick”) in connection with sales of the FDA EUA authorized BOSON Rapid SARS-CoV-2 Antigen Test Card (the “Product”) in the U.S. market.

Effective immediately, the following will take effect:

1. LumiQuick shall become the sole importer of Product to the U.S. market.
2. LumiQuick shall become the exclusive distributor of Product in the U.S. market.
3. LumiQuick will be solely responsible for selecting sub-distributor partners in the U.S. Market.
4. LumiQuick or a LumiQuick authorized sub-distributor will negotiate all Product business on behalf of Boson in the U.S. market.
5. All prior authorizations to import and distribute Product in the U.S. market shall be terminated.

“The importance of this expanded partnership cannot be understated” said Boson CEO, Changgong Zhang. Our goal is to build a trusted brand known for quality, exceptional customer service, and a transparent purchasing process. It is for these reasons that we are extremely excited about this new partnership with LumiQuick.”

Xiamen Boson Biotech Co., Ltd., founded in 2001, specializes in the development, manufacturing, and distribution of high-quality point of care tests and other immunoassay kits for the world-wide *In vitro* diagnostic market. Combining the technological, material, and labor resources of China and the U.S., Boson has exported approximately 800 million antigen tests to more than 70 countries. With a current manufacturing capacity of 10 million test per day (250 million per month) and the ability to leverage additional resources, Boson is positioned to increase capacity, as needed, to meet any increases in demand. To maximize shelf-life upon delivery, lead time from purchase order to manufacturing to delivery at a U.S.-based Boson warehouses will range from 7-10 days. More information about Boson can be found at <http://www.bosonbio.com>.

LumiQuick Diagnostics Inc., located in the heart of Silicon Valley, California, USA, develops, manufactures, and markets high quality point of care tests and other immunoassay kits for the world-wide *In vitro* diagnostic market. Through years of continuous and diligent efforts, we are proud to offer extensive product lines of rapid tests, ELISA, CLIA and raw materials. These product lines provide the immunoassays in various formats to detect infectious diseases, cardiac markers, cancer markers, drugs of abuse, fertility hormones and other disease markers. Many of the products have been FDA approved and/or CE marked and registered in different countries. More information about LumiQuick can be found at <http://www.lumiquick.com>.

Contact: Please direct all communications for Boson and LumiQuick to sales@lumiquick.com.